Lonza will provide Vaxcyte with a tailored manufacturing facility in Visp, Switzerland.

San Carlos, California: Expanding upon their current partnership, this new agreement will facilitate the global commercialization of Vaxcyte's PCV candidates, VAX-24 and VAX-31, for both pediatric and adult demographics. This agreement aligns with Vaxcyte's strategy to utilize Lonza's established infrastructure for clinical development and the imminent US introduction of VAX-24 for the adult population. Lonza will provide Vaxcyte with a specialized manufacturing suite within its Ibex Dedicate Biopark located in Visp, Switzerland. This facility will be utilized for the production of critical components, including drug substances, necessary for Vaxcyte's PCV franchise. Commencing with the late-stage clinical development of VAX-24, Vaxcyte's exclusive manufacturing facility is poised to meet the potential sustained global market demand for both adult and pediatric populations. The finalization of the design for this dedicated manufacturing facility is in its advanced stages, and the installation of equipment is projected to commence in 2024. As Lonza reaches its peak operational capacity, it is expected to generate around 300 new employment opportunities.

According to the Chief Executive Officer of Vaxcyte, “Following the successful completion of our VAX-24 Phase II adult studies, and as we prepare for Phase III clinical studies, we are excited to expand our relationship with Lonza, a pre-eminent contract development and manufacturing organization, and put into motion the key steps required to establish large-scale and long-term commercial manufacturing capacity for our PCV candidates.” In addition, the President of Lonza Biologics stated, “Having supported the early-stage clinical development of Vaxcyte’s PCV programmes, we are pleased to continue our long-standing collaboration by supporting the late-stage clinical manufacturing utilising our unique IbexDedicate offering, with the capability to provide commercial supply of their products.”

According to TechSci Research, The commercial manufacturing of Comprehensive Pneumococcal Conjugate Vaccines (PCVs) has emerged as a pivotal driver within the global healthcare sector. These vaccines, specifically designed to combat pneumococcal infections, are becoming progressively indispensable components of public health strategies on a global scale. Moreover, the market for Comprehensive Pneumococcal Conjugate Vaccines (PCVs) has been witnessing a significant surge in commercial manufacturing. The pressing need for widespread immunization programs to combat pneumococcal infections has fueled the demand for PCVs. The rising global population, particularly in developing regions, has intensified the urgency to ensure affordable access to these vaccines. This, in turn, has prompted manufacturers to invest in expanding their PCV production capacity.

Pharmaceutical giants, along with key players in the vaccine industry, have been focusing on research and development to enhance PCV formulations. These innovations have led to the introduction of new and more effective PCVs, further driving commercial manufacturing. In addition, government initiatives and global health organizations have played a pivotal role in promoting the commercial manufacturing of PCVs. They support bulk procurement programs and subsidize vaccine costs, making them more accessible to healthcare providers and patients in need.